Compare AbCellera Biologics Inc (ABCL) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Oatly Group AB - ADR — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Oatly Group AB - ADR trades at $9.38 (market cap $301.32M). The key difference: AbCellera Biologics Inc is far larger — about 7.8× Oatly Group AB - ADR's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals.
| ABCL | OTLY | |
|---|---|---|
Market Cap | $2.35B | $301.32M |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $18.54 |
52-Week Low | $2.78 | $8.03 |
Enterprise Value | $1.99B | $798.94M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
OTLY trades at $9.65, down 3.02% today, with a bullish technical signal from moving averages and ADX indicators. Revenue grew to $862.46M in 2025, but the company reported a net loss of $152.77M, with negative cash flow and high debt levels. Recent news includes a partnership with Nespresso and upcoming Q2 2026 earnings on July 22, 2026.
The outlook remains challenging due to persistent losses and cash burn, though revenue growth and a strong brand offer potential. Key risks include high leverage and competitive pressures. Analysts are divided, with 44% buy ratings but 50% hold, reflecting cautious optimism amid financial headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
